الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 152 |  |  |
| | | from | 152 | | |
Abstract
Multiple myeloma is a clonal proliferative disorder of terminally differentiated B-cell resulting in the accumulation of neoplastic plasma cells in the bone marrow. Wide variability has been observed in the prognosis of patients, leading to diverse survival durations ranging from several days to longer than 10 years. Therefore, it is important to evaluate the biological and clinical prognostic factors at the time of diagnosis to interpret the patient’s outcome and to identify patients who need more aggressive therapy.The main applications of multiparameter flow cytometry in MM are the assessment of MM progression from monoclonal gammopathy of undetermined significance, follow-up of MRD, and detection of the prognostic markers and identification of new treatment goals for MM.The present study is a single center, open label, non-randomized prospective study that was approved by the Ethical Committee of the Faculty of Medicine Mansoura University. It was conducted on 30 adult patients with newly diagnosed multiple myeloma who were attending the Hematology unit in the Oncology Center Mansoura University (OCMU) from May 2016 to January 2019. Then we used IPT markers CD38, CD138, CD19, CD45, CD56 and CD117 for detection of the number and percentage of plasma cells in those patients. The expression status of CD56 and CD117 on myeloma cells and its correlation with the clinicopathological factors, response to treatment and survival of patients was assessed.CD56 expression was found in 80% of cases and was associated with younger age of diagnosis, lower bone marrow plasma cell counts, lower levels of serum β2-microglobulin. However it didn’t reach statistically significant level because of small sample size included in the study. The study of immunophenotyping in the studied cases showed a significant association between CD45 positivity and negative CD56 expression (p=0.016).CD117 expression was found in 56.7% of cases and was associated with higher serum albumin levels (p=0.035). However, it did not show association with other baseline clinical characteristics. Lack of CD56 expression was associated with inferior PFS and OS (p=0.007 and p=0.044) respectively, and when incorporated into multivariate analysis, lack of CD56 expression showed to be a strong independent factor for shorter PFS. When patients were grouped according to co-expression of CD56 and CD117, the CD56-/CD117- group showed shorter OS and PFS (p=0.047 and p=0.035) compared to CD56+/CD117+ group.